CAMP4 Therapeutics Corporation Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings
CAMP4 Therapeutics Corporation (CAMP) reported Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings of -$20.93 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings · last filed 2026-08-13
- CAMP4 Therapeutics Corporation fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, gain (loss) included in earnings for the quarter ending 2026-06-30 was -$20.93M.
- CAMP4 Therapeutics Corporation fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, gain (loss) included in earnings for the quarter ending 2026-03-31 was -$6.19M.
- CAMP4 Therapeutics Corporation fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, gain (loss) included in earnings for the quarter ending 2025-12-31 was -$28.03M.
- CAMP4 Therapeutics Corporation fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, gain (loss) included in earnings for fiscal 2025 was -$29.83M.
| Period end | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings 3 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings 6 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings 9 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$20.93M 10-Q · filed 2026-08-13 | -$27.10M 10-Q · filed 2026-08-13 | -$55.15M derived: sum of 3 quarters · filed 2026-08-13 | |
| 2026-03-31 | -$6.19M 10-Q · filed 2026-08-13 | -$34.22M derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2025-12-31 | -$28.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$29.83M 10-K · filed 2026-03-05 | ||
| 2025-09-30 | -$1.80M 10-Q · filed 2025-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |